<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Oestrogens: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i636.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i636.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i636.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i634.htm" title="Previous: Isosorbide Mononitrate">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i640.htm" title="Next: Estradiol">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i636">Oestrogens</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Oestrogens</b>
          has the following interaction information:
        </p><div>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i2.htm" name="_2">ACE Inhibitors</a></td><td> oestrogens antagonise hypotensive effect of ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm" name="_15">Adrenergic Neurone Blockers</a></td><td> oestrogens antagonise hypotensive effect of adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i26.htm" name="_26">Alpha-blockers</a></td><td> oestrogens antagonise hypotensive effect of alpha-blockers </td><td></td></tr><tr><td><a href="41001i107.htm" name="_107">Angiotensin-II Receptor Antagonists</a></td><td> oestrogens antagonise hypotensive effect of angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td> oestrogens antagonise antidepressant effect of tricyclics (but side-effects of tricyclics  possibly increased due to increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i264.htm" name="_264">Antidiabetics</a></td><td> oestrogens antagonise hypoglycaemic effect of antidiabetics </td><td></td></tr><tr><td><a href="41001i293.htm" name="_293">Antifungals, Imidazole</a></td><td>anecdotal reports of contraceptive failure when  oestrogens given with imidazoles </td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td class="cBV"><b>possible contraceptive failure of hormonal contraceptives containing  oestrogens when given with aprepitant (alternative contraception recommended)</b></td><td></td></tr><tr><td><a href="41001i440.htm" name="_440">Beta-blockers</a></td><td> oestrogens antagonise hypotensive effect of beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>possible contraceptive failure of hormonal contraceptives containing  oestrogens when given with boceprevir (alternative contraception recommended)</b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td class="cBV"><b>possible contraceptive failure of hormonal contraceptives containing  oestrogens when given with bosentan (alternative contraception recommended)</b></td><td></td></tr><tr><td><a href="41001i466.htm" name="_466">Calcium-channel Blockers</a></td><td> oestrogens antagonise hypotensive effect of calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by carbamazepine (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td> oestrogens possibly increase plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i482.htm" name="_482">Clonidine</a></td><td> oestrogens antagonise hypotensive effect of clonidine </td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td>oral contraceptives containing  oestrogens increase plasma concentration of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td> oestrogens may enhance or reduce anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i412.htm" name="_412">Diazepam</a></td><td> oestrogens possibly increase plasma concentration of diazepam </td><td></td></tr><tr><td><a href="41001i524.htm" name="_524">Diuretics</a></td><td> oestrogens antagonise diuretic effect of diuretics </td><td></td></tr><tr><td><a href="41001i1153.htm">Eslicarbazepine</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by eslicarbazepine (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i291.htm" name="_291">Griseofulvin</a></td><td>anecdotal reports of contraceptive failure and menstrual irregularities when  oestrogens given with griseofulvin </td><td></td></tr><tr><td><a href="41001i763.htm" name="_763">Hydralazine</a></td><td> oestrogens antagonise hypotensive effect of hydralazine </td><td></td></tr><tr><td><a href="41001i283.htm" name="_283">Lamotrigine</a></td><td class="cBV"><b> oestrogens reduce plasma concentration of lamotrigine—consider increasing dose of lamotrigine</b></td><td></td></tr><tr><td><a href="41001i1114.htm" name="_1114">Melatonin</a></td><td> oestrogens increase plasma concentration of melatonin </td><td></td></tr><tr><td><a href="41001i611.htm" name="_611">Methyldopa</a></td><td> oestrogens antagonise hypotensive effect of methyldopa </td><td></td></tr><tr><td><a href="41001i764.htm" name="_764">Minoxidil</a></td><td> oestrogens antagonise hypotensive effect of minoxidil </td><td></td></tr><tr><td><a href="41001i847.htm">Modafinil</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by modafinil (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i615.htm" name="_615">Moxonidine</a></td><td> oestrogens antagonise hypotensive effect of moxonidine </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by nelfinavir (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by nevirapine (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i631.htm" name="_631">Nitrates</a></td><td> oestrogens antagonise hypotensive effect of nitrates </td><td></td></tr><tr><td><a href="41001i900.htm">Oxcarbazepine</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by oxcarbazepine (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i223.htm" name="_223">Phenindione</a></td><td class="cBV"><b> oestrogens antagonise anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by phenobarbital (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by phenytoin (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i199.htm">Rifamycins</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by rifamycins (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions do not apply to rifaximin</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by ritonavir (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i686.htm" name="_686">Ropinirole</a></td><td> oestrogens increase plasma concentration of ropinirole </td><td></td></tr><tr><td><a href="41001i1102.htm">Rufinamide</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by rufinamide (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i687.htm" name="_687">Selegiline</a></td><td class="cBV"><b> oestrogens increase plasma concentration of selegiline—manufacturer of selegiline advises avoid concomitant use</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i765.htm" name="_765">Sodium Nitroprusside</a></td><td> oestrogens antagonise hypotensive effect of sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i848.htm" name="_848">Somatropin</a></td><td> oestrogens (when used as oral replacement therapy) may increase dose requirements of somatropin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>contraceptive effect of  oestrogens reduced by St John's wort (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i292.htm" name="_292">Terbinafine</a></td><td>occasional reports of breakthrough bleeding when  oestrogens (used for contraception) given with terbinafine </td><td></td></tr><tr><td><a href="41001i734.htm" name="_734">Theophylline</a></td><td> oestrogens increase plasma concentration of theophylline (consider reducing dose of theophylline)</td><td></td></tr><tr><td><a href="41001i935.htm" name="_935">Thyroid Hormones</a></td><td> oestrogens may increase requirements for thyroid hormones in hypothyroidism</td><td></td></tr><tr><td><a href="41001i805.htm" name="_805">Tizanidine</a></td><td> oestrogens possibly increase plasma concentration of tizanidine (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i285.htm">Topiramate</a></td><td class="cBV"><b>metabolism of  oestrogens accelerated by topiramate (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td></td></tr><tr><td><a href="41001i948.htm" name="_948">Voriconazole</a></td><td> oestrogens increase plasma concentration of voriconazole </td><td></td></tr></tbody></table><p><b>Estradiol</b> belongs to
      <b>Oestrogens</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  estradiol increased by erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr></tbody></table><p><b>Estriol</b> belongs to
      <b>Oestrogens</b>
          but has no specific interaction information.
        </p><p><b>Estrone</b> belongs to
      <b>Oestrogens</b>
          but has no specific interaction information.
        </p><p><b>Ethinylestradiol</b> belongs to
      <b>Oestrogens</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>plasma concentration of  ethinylestradiol increased by atazanavir </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>plasma concentration of  ethinylestradiol increased by atorvastatin </td><td></td></tr><tr><td><a href="41001i1108.htm">Colesevelam</a></td><td>absorption of  ethinylestradiol reduced by colesevelam </td><td>Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </td></tr><tr><td><a href="41001i960.htm">Etoricoxib</a></td><td>plasma concentration of  ethinylestradiol increased by etoricoxib </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td>plasma concentration of  ethinylestradiol increased by rosuvastatin </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td> ethinylestradiol possibly increases plasma concentration of tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  ethinylestradiol possibly reduced by telaprevir—manufacturer of telaprevir advises additional contraceptive precautions</b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td> ethinylestradiol possibly reduces plasma concentration of valproate </td><td></td></tr></tbody></table><p><b>Mestranol</b> belongs to
      <b>Oestrogens</b>
          but has no specific interaction information.
        </p><p><b>Oestrogens, conjugated</b> belongs to
      <b>Oestrogens</b>
          but has no specific interaction information.
        </p></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i640.htm" title="Estradiol">Estradiol</a></li><li><a href="41001i641.htm" title="Estriol">Estriol</a></li><li><a href="41001i642.htm" title="Estrone">Estrone</a></li><li><a href="41001i638.htm" title="Ethinylestradiol">Ethinylestradiol</a></li><li><a href="41001i639.htm" title="Mestranol">Mestranol</a></li><li><a href="41001i643.htm" title="Oestrogens, conjugated">Oestrogens, conjugated</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i634.htm">Previous: Isosorbide Mononitrate</a> | <a class="top" href="41001i636.htm#">Top</a> | <a accesskey="]" href="41001i640.htm">Next: Estradiol</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>